Related Experiment Video
Updated: May 18, 2026

10:54
Extraction of Plant-based Capsules for Microencapsulation Applications
Published on: November 9, 2016
Prenylated phloroglucinol derivatives from Hypericum sampsonii
Wen-bo Xin1, Xiao-hua Man, Cheng-jian Zheng
1Department of Pharmacognosy, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China.
Fitoterapia
|September 18, 2012
Summary
Six new compounds from Hypericum sampsonii, sampsonols A-F, were identified. Sampsonols A and B exhibit significant cytotoxicity, while sampsonols C and F display potent anti-inflammatory effects.
Area of Science:
- Natural Product Chemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Hypericum sampsonii is a plant species with potential medicinal properties.
- Acylphloroglucinol derivatives are a class of natural products known for diverse biological activities.
Purpose of the Study:
- To isolate and characterize new acylphloroglucinol derivatives from Hypericum sampsonii.
- To evaluate the in vitro cytotoxic and anti-inflammatory activities of the isolated compounds.
Main Methods:
- Isolation of compounds using petroleum ether extraction.
- Structure elucidation through extensive spectroscopic analyses (e.g., NMR, MS).
- In vitro assays for cytotoxicity against human tumor cell lines and anti-inflammatory activity (nitric oxide inhibition).
Main Results:
- Six new acylphloroglucinol derivatives, named sampsonols A-F (1-6), were successfully isolated.
- Sampsonols A and B (1 and 2) demonstrated significant cytotoxicity against four human tumor cell lines (IC50: 13-28 μM).
- Sampsonols C and F (3 and 6) exhibited potent inhibition of lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophages (IC50: 27.3 and 29.3 μM, respectively).
Conclusions:
- The study successfully identified novel acylphloroglucinol derivatives from Hypericum sampsonii.
- Sampsonols A and B possess promising cytotoxic properties, warranting further investigation for cancer therapy.
- Sampsonols C and F show potential as anti-inflammatory agents, particularly for conditions involving macrophage-mediated inflammation.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Metabolism: Phase II Reactions
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
